相关实验视频
Updated: May 28, 2025

11:29
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
10.8K
类似胰岛素的生长因子2 mRNA结合蛋白2 (IGF2BP2) 通过调节AR-V7 mRNA稳定性来促进抵抗割的前列腺癌进展
Taruna Saini1, Devesh Srivastava1, Rajnikant Raut1
1Department of Biotechnology, Indian Institute of Technology Hyderabad, Kandi, Sangareddy, India.
Cancer reports (Hoboken, N.J.)
|February 13, 2025
概括
胰岛素样生长因子2 mRNA结合蛋白2 (IGF2BP2) 通过稳定雄激素受体变体7 (AR-V7) mRNA.促进割抵抗性前列腺癌 (CRPC). 向IGF2BP2可能为CRPC提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 由于出现了雄激素受体变体7 (AR-V7) 的出现,抗化前列腺癌 (CRPC) 的治疗具有挑战性.
- 由于AR-V7缺乏联体结合域,因此它对标准的雄激素剥夺疗法具有抗性.
- 在CRPC中调节AR-V7表达和功能的机制尚未完全理解.
研究的目的:
- 研究IGF2BP2在调节AR-V7表达和CRPC进展中的作用.
- 探索IGF2BP2作为CRPC的潜在治疗点.
主要方法:
- 来自CRPC患者的临床mRNA表达数据的分析.
- 在体外实验涉及IGF2BP2敲击和CRPC细胞过度表达的实验.
- 试验包括qRT-PCR,免疫斑块,殖民地形成,MTT,RIP-qPCR和阿提诺米辛-D治疗.
- 进行了IGF2BP2的域删除分析.
主要成果:
- 在CRPC中,IGF2BP2是上调调的,与较高的格里森分数相关.
- 抑制IGF2BP2会降低AR-V7及其位的调节,从而增加对胺胺的敏感性.
- 过度表达IGF2BP2增强了AR-V7的表达,并产生了对酶胺的耐药性.
- IGF2BP2与AR-V7内部剪接增强剂结合,稳定其mRNA.
结论:
- IGF2BP2是CRPC中AR-V7表达和稳定性的关键调节者.
- 在CRPC治疗中,IGF2BP2代表了一个新的治疗点.
- 向IGF2BP2可以克服前列腺癌中对恩扎胺的耐药性.
相关概念视频
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Experimental RNAi
6.0K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.0K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Negative Regulator Molecules
35.1K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.1K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K

